» Articles » PMID: 39106314

U.S. Medical Eligibility Criteria for Contraceptive Use, 2024

Overview
Journal MMWR Recomm Rep
Specialty Public Health
Date 2024 Aug 6
PMID 39106314
Authors
Affiliations
Soon will be listed here.
Abstract

The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

Citing Articles

Cardiac Valve Prosthesis and Pregnancy: Challenges and Strategies.

Nomura M Arq Bras Cardiol. 2025; 122(1):e20240602.

PMID: 40052972 PMC: 11834729. DOI: 10.36660/abc.20240602.


Therapeutic selection for abnormal uterine bleeding with ovulatory dysfunction: a cross-sectional study in Chinese women.

Zhao X, Luo M, Tian Q Future Sci OA. 2025; 11(1):2459001.

PMID: 39920891 PMC: 11812333. DOI: 10.1080/20565623.2025.2459001.


Perspectives on Contraception, Pregnancy, and Reproductive Health Counseling from Young Women With Inflammatory Bowel Disease.

Brenner E, Grewe M, Berenblum Tobi C, Bryant A, Dubinsky M, Zhang X Crohns Colitis 360. 2025; 7(1):otae078.

PMID: 39760126 PMC: 11700615. DOI: 10.1093/crocol/otae078.


Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices.

Skeith L, Bates S Hematology Am Soc Hematol Educ Program. 2024; 2024(1):644-651.

PMID: 39644023 PMC: 11665608. DOI: 10.1182/hematology.2024000591.


"I am putting my fear on them subconsciously": a qualitative study of contraceptive care in the context of abortion bans in the U.S.

Zia Y, Somerson E, Folse C, Alvarez A, Albergate Davis K, Comfort A Reprod Health. 2024; 21(1):171.

PMID: 39581967 PMC: 11587542. DOI: 10.1186/s12978-024-01908-9.


References
1.
DeSano Jr E, Hurley S . Possible interactions of antihistamines and antibiotics with oral contraceptive effectiveness. Fertil Steril. 1982; 37(6):853-4. DOI: 10.1016/s0015-0282(16)46350-8. View

2.
. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38(1):1-211. DOI: 10.1177/0333102417738202. View

3.
Cobb K, Bachrach L, Sowers M, Nieves J, Greendale G, Kent K . The effect of oral contraceptives on bone mass and stress fractures in female runners. Med Sci Sports Exerc. 2007; 39(9):1464-73. DOI: 10.1249/mss.0b013e318074e532. View

4.
Barditch-Crovo P, Trapnell C, Ette E, Zacur H, Coresh J, Rocco L . The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999; 65(4):428-38. DOI: 10.1016/S0009-9236(99)70138-4. View

5.
Bernatsky S, Clarke A, Ramsey-Goldman R, Joseph L, Boivin J, Rajan R . Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology (Oxford). 2004; 43(9):1178-81. DOI: 10.1093/rheumatology/keh282. View